ALNYLAM PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $33.0B
- as of Sep 30, 2026
- Shares Outstanding
- 133.8M
- Free Float
- 99.5%
Income Statement
- Revenue
- $3.7B
- Operating Income
- $501.6M
- Net Income
- $313.7M
- EBITDA
- $557.2M
- Revenue Growth, 3Y
- 53.0%
- FCF Margin, 3Y Avg
- 4.3%
- FCF Margin, Worst Year
- -1.9%
Cash Flow
- Free Cash Flow
- $465.4M
- FCF Yield
- 1.4%
- Owner FCF Yield
- 0.4%
Balance Sheet
- Cash & Equivalents
- $1.7B
Returns & Capital
- SBC, 3Y Avg
- $280.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.7B | $465.4M | 12.5% |
| FY2024 | $2.2B | -$42.6M | -1.9% |
| FY2023 | $1.8B | $41.9M | 2.3% |
| FY2022 | $1.0B | -$613.3M | -59.1% |
| FY2021 | $844.3M | -$718.1M | -85.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back